Results
1 -
10 of
11SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake2 carrier, which mediates increased cytotoxicity, Cancer Chemotherapy and Pharmacology Utilization of the HTSCA and CFU-C assay to identify two new 2-chloroethylnitrosourea congeners of amino acid amides with increased in vitro activity against human glioma compared with BCNU, Cancer Chemotherapy and Pharmacology Antitumor effect of sarcnu in a 06-methylguanine-DNA methyltransferase positive human glioma xenograft model, Chinese Journal of Cancer Research Human Tumor Xenograft Models in NCI Drug Development, Anticancer Drug Development Guide Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs, Cancer Chemotherapy and Pharmacology Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat, Cancer Chemotherapy and Pharmacology SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group, Investigational New Drugs Enhanced Antitumor Activity of SarCNU in Comparison to BCNU in an Extraneuronal Monoamine Transporter Positive Human Glioma Xenograft Model, Journal of Neuro-Oncology Antitumor Efficacy of SarCNU in a Human Glioma Xenograft Model Expressing Both MGMT and Extraneuronal Monoamine Transporter, Journal of Neuro-Oncology Relationship Between Drug Delivery and the Intra-arterial Infusion Rate of SarCNU in C6 Rat Brain Tumor Model, Journal of Neuro-Oncology